NOVEMBER 10, 2013 – 2PM PST
HOW TO MAKE LUNG CANCER A CHRONICALLY MANAGED DISEASE IN 10 YEARS
THE NEXT DECADE IN LUNG CANCER
Moderator: Laurence Heifetz, MD – Medical Director, Gene Upshaw Memorial Tahoe Cancer Center
For Dr. Heifetz, helping cancer patients has become his life’s work, providing what he calls “a wonderful sense of satisfaction.” After 30 years in oncology, Dr. Heifetz is still admired for his personal and honest approach.
He was a founding partner of Tower Hematology Oncology Medical Group at Cedars-Sinai Medical Center in Los Angeles, California, and is a clinical professor at UC Davis.He has developed solid relationships with leaders from regional cancer centers of excellence including the Stanford Cancer Center, UC Davis Cancer Center, and UC San Francisco Cancer Center, among others. These relationships have proved invaluable for providing state-of-the-art cancer care in our local communities.
A musician in his free time, Dr. Heifetz plays the piano with a blues band. He is also on the Board of Directors and volunteers for Operation U.S.A, an organization that provides medical relief to third-world countries. His wife, Daphne Palmer, MD, is a radiation oncologist. They have two grown children.
Andrew Allen, BM, BCh, MA, MRCP, PhD – Clovis Oncology
Dr. Allen is the Executive Vice President of Clinical and Pre-Clinical Development and Chief Medical Officer at Clovis Oncology.
He is one of the co-founders and has served as Executive Vice President of Clinical and Pre-Clinical Development and Chief Medical Officer since the inception. Previously, Dr. Allen served in the same role at Pharmion Corporation, beginning in 2006. From 2004 through 2006, Dr. Allen served as Vice President of BioPharma Development and Head of the Oncology Therapeutic Unit for Chiron Corporation. Previously, Dr. Allen served as global project head in Abbott Laboratories’ oncology franchise, and prior to that he progressed through positions of increasing responsibility at the management consulting firm McKinsey & Company, with a focus on oncology strategy. Dr. Allen serves on the board of directors of Nodality, Inc., a privately-held biotechnology company.
Dr. Allen qualified in medicine at Oxford University and earned his PhD from the Imperial College of Science, Technology and Medicine in London. Dr. Allen also obtained post-graduate internal medicine qualification as a Member of Royal College of Physicians (MRCP).
David Jablons, MD—UCSF
David M. Jablons, MD, is Professor and Chief of Thoracic Surgery at the University of California, San Francisco, and Ada Distinguished Professor of Thoracic Oncology at the UCSF Helen Diller Comprehensive Cancer Center, where he also serves as Program Leader of Thoracic Oncology.
Dr. Jablons received his undergraduate degree from Yale University and his medical degree from Albany Medical College of Union University. He has also trained at numerous highly-regarded institutions including Tufts-New England Medical Center, Oak Knoll Naval Hospital, the Surgery Branch of NCI, Cornell University Medical Center, New York Hospital/Memorial Sloan Kettering Cancer Center, and Brigham & Women’s Hospital.
Dr. Jablons established the UCSF/UC Davis Thoracic Oncology Conference, one of the oldest and longest running didactic conferences in the field. He also helped found the International Pan Pacific Lung Cancer Conference. He is a strong supporter of international efforts to expand lung cancer research, and helped start the China Clinical Trials Consortium (CCTC). He also co-founded the Bonnie J. Addario Lung Cancer Foundation and the Addario Lung Cancer Medical Institute.
Dr. Jablons leads a team of scientists developing molecularly targeted therapies for lung cancer and mesothelioma. Key research areas include the Wnt and Hedgehog (Hh) pathways, and stem cell signaling targets. The Thoracic Oncology Tissue Bank is one of the largest such repositories in the U.S. and serves as a hub for interdisciplinary collaboration. Dr. Jablons is also a principal investigator on two NIH R01 grants and has authored over 100 peer-reviewed research papers. In addition, he serves as a reviewer on several NIH study groups.
Ita Laird-Offringa, PhD—USC
Ite Laird-Offringa, PhD, is an Associate Professor of Surgery and of Biochemistry and Molecular Biology at Norris Comprehensive Cancer Center at the University of Southern California (USC), Keck School of Medicine. She is also the Director of the Program in Biomedical and Biological Sciences at USC. She earned her Ph.D. from the University of Leiden, The Netherlands, and conducted postdoctoral work at Harvard Medical School.
She joined the USC faculty in 1996. She is a member of many national and international professional and advocate societies, including the American Association for Cancer Research, the International Association for the Study of Lung Cancer, and the National Lung Cancer Partnership, and she serves as a reviewer on the NIH/NCI Cancer Genetics study section.
Dr. Laird-Offringa is committed to the development of better tools for early lung cancer detection. Her laboratory’s current research in lung cancer focuses on the identification of cancer-specific changes in antibodies and in DNA methylation, a reversible alteration of DNA that can affect gene expression. The obtained information is used for biomarker development and to gain insight into the sequential molecular steps that happen during the development of lung cancer.
The Laird-Offringa laboratory is funded by two NIH R01 grants and by generous donations and grants from several private foundations and individuals. In her work, she collaborates with pathologists, oncologists, surgeons, epidemiologists and a variety of other scientists.
Harvey Pass, MD—NYU
Harvey I. Pass, MD, is Professor of Thoracic Oncology, Vice-Chair Research, Department of Cardiology, and first Division Chief of General Thoracic Surgery at NYU School of Medicine. He joined NYU Medical Center in 2005 to lead the Division of Thoracic Surgery and Thoracic Oncology. His previous positions include Chief, Thoracic Oncology at the Karmanos Cancer Institute, and Head of the Thoracic Oncology Section of the National Cancer Institute (NCI) for the National Institutes of Health.
Dr. Pass received his B.A. from Johns Hopkins University and his M.D. from Duke University. He completed his surgical residency at Duke and University of Mississippi. He completed his residency in Cardiothoracic Surgery at the Medical University of South Carolina. Dr. Pass also completed a fellowship in Thoracic Oncology at NCI.
Dr. Pass has published over 300 manuscripts in peer-reviewed journals, including The New England Journal of Medicine regarding the discovery of osteopontin as a possible early detection biomarker for mesothelioma. He is an editor of Lung Cancer: Principles and Practice, Surgery: Basic Science and Clinical Evidence, Oncology: An Evidence Based Approach, and Malignant Mesothelioma: Advances in Pathogenesis, Diagnosis, and Translational Therapies. Dr. Pass is Associate Editor for the Journal of
Thoracic Oncology, Surgical Editor for Clinical Lung Cancer and a member of the editorial board for Clinical Cancer Research.
Dr. Pass is presently on the Board of Directors for the International Association for the Study of Lung Cancer, the International Mesothelioma Interest Group, the Lung Cancer Alliance, and the Mesothelioma Foundation.